447 related articles for article (PubMed ID: 15580242)
1. Cancer vaccines: pessimism in check.
Mocellin S; Mandruzzato S; Bronte V; Marincola FM
Nat Med; 2004 Dec; 10(12):1278-9; author reply 1279-80. PubMed ID: 15580242
[No Abstract] [Full Text] [Related]
2. Cancer vaccines: pessimism in check.
Timmerman JM; Levy R
Nat Med; 2004 Dec; 10(12):1279; author reply 1279-80. PubMed ID: 15682512
[No Abstract] [Full Text] [Related]
3. Immunotherapy of metastasis.
Dallal RM; Lotze MT
Surg Oncol Clin N Am; 2001 Apr; 10(2):433-47, xi. PubMed ID: 11382596
[TBL] [Abstract][Full Text] [Related]
4. Cellular and humoral immune responses of cancer patients to defined tumor antigens.
Jäger D; Jäger E; Bert F; Knuth A
Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025
[No Abstract] [Full Text] [Related]
5. [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].
Jäger E; Jäger D; Knuth A
Dtsch Med Wochenschr; 2001 Sep; 126(37):1011-6. PubMed ID: 11555776
[No Abstract] [Full Text] [Related]
6. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
7. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
Nelson B
Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
[No Abstract] [Full Text] [Related]
8. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
9. New frontiers in cell-based immunotherapy of cancer.
D'Elios MM; Del Prete G; Amedei A
Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
[TBL] [Abstract][Full Text] [Related]
10. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
Neeson P; Paterson Y
Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy: moving beyond current vaccines.
Rosenberg SA; Yang JC; Restifo NP
Nat Med; 2004 Sep; 10(9):909-15. PubMed ID: 15340416
[TBL] [Abstract][Full Text] [Related]
12. Cyclins against cancer: a novel family of tumor antigens?
Klein-González N; Kondo E; von Bergwelt-Baildon MS
Immunotherapy; 2010 Sep; 2(5):595-7. PubMed ID: 20874640
[No Abstract] [Full Text] [Related]
13. Cancer-testis antigens: targets for cancer immunotherapy.
Chen YT; Old LJ
Cancer J Sci Am; 1999; 5(1):16-7. PubMed ID: 10188055
[No Abstract] [Full Text] [Related]
14. Cancer vaccines: preclinical studies and novel strategies.
Palena C; Abrams SI; Schlom J; Hodge JW
Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
[TBL] [Abstract][Full Text] [Related]
15. Tumor vaccine: current trends in antigen specific immunotherapy.
Baral R
Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
[TBL] [Abstract][Full Text] [Related]
16. Tumor immunology at the service of cancer immunotherapy.
Finn OJ
Curr Opin Immunol; 2004 Apr; 16(2):127-9. PubMed ID: 15023402
[No Abstract] [Full Text] [Related]
17. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
Van den Eynde B
Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N; Zoernig I; Jäger D
Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.
Fournier P; Schirrmacher V
Expert Rev Vaccines; 2009 Jan; 8(1):51-66. PubMed ID: 19093773
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of prostate cancer.
Doehn C
Eur Urol; 2008 Apr; 53(4):681-3; discussion 684-5. PubMed ID: 18248878
[No Abstract] [Full Text] [Related]
[Next] [New Search]